ALK and non-small cell lung carcinoma: The independent and possibly synergistic effects of both the ALK fusion variant and TP53 mutations (as well as other, yet to be identified molecular features) on the clinical course of ALK+ NSCLC patients [18] mean that considerable biological and clinical variability is to be expected, if a study would take only one of these molecular factors into account.